Coverage
-
February 16, 2018
A New Jersey federal judge on Thursday tossed a proposed class action alleging that Insmed Inc. misled investors over the likelihood that a lung disease drug would gain market approval in Europe, ruling that the biopharmaceutical company's alleged misstatements and omissions didn't meet the standards for securities law claims.
1 other articles on this case.
View all »